**Supplementary Table 5** Comparison of the aMAP-CT, model with aMAP and liver signatures (aMAP+liver), model with aMAP and spleen signatures (aMAP+spleen), and aMAP model in HCC risk stratification. Abbreviations: HCC, hepatocellular carcinoma.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Models** | **High-risk,** **n (%)** |  | **HR** **(95% CI)** |  | **3-year cumulative incidence of HCC** |  | **1-year cumulative incidence of HCC** |
|  |  | **High-risk group** | **Low-risk group** |  | **High-risk group** | **Low-risk group** |
| aMAP-CT | 183(7.6%) |  | 12.3(5.8-26.0) |  | 26.3% | 1.7% |  | 13.3% | 0.7% |
| aMAP+liver | 271(11.2%) |  | 4.0(2.2-7.1) |  | 12.8% | 2.4% |  | 6.3% | 1.1% |
| **aMAP+spleen** | **163****(6.8%)** |  | **3.9****(1.7-8.7)** |  | **12.2%** | **3.0%** |  | **7.5%** | **1.3%** |
| aMAP | 1014(42.1%) | 　 | 3.1 (2.2-4.5) | 　 | 5.9% | 1.9% | 　 | 2.9% | 0.8% |